FibroBiologics Granted Extension by Nasdaq to Regain Compliance
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) received a Nasdaq Hearings Panel extension to regain compliance and maintain its Nasdaq Capital Market listing. The company must meet the $2.5 million equity standard by Feb 27, 2026, achieve a minimum bid price of $1.00 by Apr 13, 2026, and satisfy all continued-listing criteria by Apr 13, 2026. Trading of FBLG shares continues uninterrupted.
Positive
- Nasdaq extension granted to retain listing
- $2.5M equity standard deadline set for Feb 27, 2026
- Minimum bid price target of $1.00 due Apr 13, 2026
Negative
- Failure to meet $2.5M equity standard risks delisting
- Short Feb 27, 2026 deadline to raise equity
- Failure to reach $1.00 bid by Apr 13, 2026 could trigger delisting
News Market Reaction – FBLG
In the Feb 23 session, FBLG gained 2.02%, reflecting a moderate positive market reaction. Argus tracked a peak move of +27.5% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Conference presentation | Positive | +6.2% | CEO selected to present at A4LI H-SPAN Summit at Georgetown. |
| Feb 05 | Patent issuance | Positive | -9.2% | Canadian patent granted for fibroblast-based cachexia treatment platform. |
| Jan 20 | Investor conference | Neutral | -3.7% | Company scheduled to present at DealFlow Discovery Conference for visibility. |
| Jan 07 | Shareholder letter | Positive | +32.3% | Update on 2025 clinical, IP, manufacturing and financing milestones, plus debt payoff. |
| Jan 06 | Investor conference | Neutral | +6.8% | CEO presentation at BFC Global healthcare and investment conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent headlines are mostly corporate visibility and IP/strategy updates, with four of five events seeing price moves that align with their generally positive or neutral tone, and one clear divergence on patent news.
Over the past few months, FibroBiologics has focused on conferences, patents, and strategic updates. A shareholder letter on Jan 7, 2026 outlining clinical and financing progress coincided with a 32.27% gain, while patent news on Feb 5, 2026 saw a 9.2% decline despite seemingly positive content. Several conference presentations (Jan 6, Jan 20, Feb 10) produced modest, generally aligned moves, framing today’s Nasdaq compliance extension within a backdrop of ongoing corporate positioning and capital-market efforts.
Key Terms
nasdaq capital market regulatory
minimum bid price requirement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it received a favorable determination from a Nasdaq Hearings Panel granting an extension to regain compliance for the continued listing of the Company’s common stock on The Nasdaq Capital Market (“Nasdaq”).
This provides FibroBiologics with a clear path to maintaining its listing on Nasdaq, subject to the Company satisfying the following conditions: meeting the equity standard of
This determination has no immediate effect on the listing or trading of the Company's shares of common stock, which will continue to trade on Nasdaq under the symbol “FBLG.”
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s intent or ability to regain compliance with the applicable Nasdaq rules and the continued trading of the Company’s shares of common stock on Nasdaq. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) FibroBiologics’ ability to manufacture its product candidates. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
